Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Reasons to Add Cardinal Health (CAH) to Your Portfolio Now

The Consumer Health Logistics Center will be located in Central Ohio and serve as a centralized hub for distribution of consumer health products COLUMBUS, Ohio , April 2, 2024 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) announced that construction has begun for a new 350,000 square-foot logistics center in Columbus, Ohio, that will serve as a centralized replenishment center for the distribution of over-the-counter consumer health products in support of its core pharmaceutical business. Located in the Rickenbacker Global Logistics Park, the Consumer Health Logistics Center will be the fourth Cardinal Health distribution facility in Central Ohio, along with its corporate headquarters in Dublin, Ohio.

Cardinal Health announces location of pharmaceutical distribution center for over-the-counter products

Asbury Automotive Group

Cencora Inc

General Motors

We believe that stocks like General Motors (GM), Cardinal Health (CAH), Cencora (COR), Alta Equipment (ALTG) and Asbury (ABG) should be on an investor's watchlist.

5 Broker-Loved Stocks That Hold Promise Despite Volatility

Applied Materials

Installed Building Products

NetApp

Ralph Lauren

NetApp (NTAP), Installed Building (IBP), Ralph Lauren (RL), Applied Materials (AMAT), and Cardinal Health (CAH) could outperform the market this year.

5 Solid Dividend Growth Stocks to Buy

DUBLIN, Ohio , March 26, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2024 on May 2, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m.

Cardinal Health to Announce Third-Quarter Results for Fiscal Year 2024 on May 2

Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.

3 Reasons Growth Investors Will Love Cardinal (CAH)

Hercules Capital

The Cash Cow Cavalry: 3 Stocks Leading the Charge to Profitability

Atmos Energy

Balchem

Casey's General Stores

Colgate-Palmolive

Low-beta stocks like Atmos Energy Corporation (ATO), Balchem Corporation (BCPC), Cardinal Health, Inc. (CAH), Casey's General Stores, Inc. (CASY) and Colgate-Palmolive Company (CL) are a safe bet amid the ongoing market volatility.

5 Low-Beta Stocks for Safe Returns as Inflation Rises Again

DUBLIN, Ohio , March 15, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced that the company has received approval by the Science Based Targets initiative (SBTi) for its near-term science-based greenhouse gas (GHG) emissions reduction targets. Targets are considered science-based if they align with what the latest climate science says is necessary to limit global warming to 1.5°C above pre-industrial levels.

Cardinal Health announces approved science-based climate targets; expands focus across the supply chain

Forestar Group

SkyWest

Undervalued stocks are typically always a solid investment option in a bullish or bearish market due to the fact that they offer considerable upside.  Solid fundamentals are the backbone of a company's overall success.

The 3 Most Undervalued Stocks With Solid Fundamentals to Buy in March 2024

Cardinal Health, Inc. (CAH) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)

Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.

Cardinal Health (CAH) Hits 52-Week High: What's Driving It?

Centene

Deutsche Bank

Group 1 Automotive

We believe that stocks like General Motors (GM), Cardinal Health (CAH), Deutsche Bank (DB), Group 1 (GPI) and Centene (CNC) should be on an investor's watchlist.

5 Stocks Favored by Brokers Amid Current Uncertainty

Iron Mountain

Toll Brothers

Cardinal Health (CAH), Toll Brothers (TOL), Iron Mountain (IRM), NetApp (NTAP) and Ralph Lauren (RL) have strong dividend growth prospects.

5 Dividend Stocks With High Growth Prospects

PagSeguro Digital

Powell Industries

POWL, CAH and PAGS made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 8, 2023.

Best Growth Stocks to Buy for March 8th

NVIDIA

PAGS, CAH and NVDA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 6, 2023.

Best Growth Stocks to Buy for March 6th

Cigna

W. R. Berkley

Targeting low-beta stocks can provide a valuable layer of stability for portfolios. After all, defense wins ballgames.

3 Top-Ranked Stocks to Buy for Stability

American Water Works

Consolidated Water

Ensign Group

Investing in defensive stocks like The Ensign Group (ENSG), Cardinal Health (CAH), Consolidated Water (CWCO), Colgate-Palmolive (CL) and American Water Works, Inc. (AWK) is a safe bet as consumer sentiment is once again sinking.

5 Defensive Stocks to Buy as Consumer Sentiment Dips Again

PAGS, CAH and NVDA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 4, 2023.

Best Growth Stocks to Buy for March 4th

Carrols Restaurant Group

SPXC, CAH and TAST made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 1, 2023.

Best Momentum Stocks to Buy for March 1st

Banco Macro

Royal Caribbean Cruises

Rithm Capital Corp

BMA, CAH, RCL, SPXC and RITM have been added to the Zacks Rank #1 (Strong Buy) List on March 1, 2023.

New Strong Buy Stocks for March 1st

BMA, CAH and RITM made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 1, 2023.

Best Income Stocks to Buy for March 1st

Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Cardinal Health, Inc. (CAH) Hits Fresh High: Is There Still Room to Run?

Study reveals impact of dramatic increase in commercially available biosimilars and progress in the areas of patient accessibility and treatment affordability DUBLIN, Ohio , Feb. 29, 2024 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) released its 2024 Biosimilars Report: insights on a pivotal year of evolution and expansion, an analysis of key recent economic, competitive, legislative and societal developments in biosimilars. The publication highlights legislative developments and new treatments, including adalimumab biosimilars.

Cardinal Health annual research report examines milestone year in biosimilars

DUBLIN, Ohio , Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1. Mr. Azelby joins the board with over 30 years of experience, including as a Chief Executive Officer and board member for large, matrixed organizations in the biopharmaceutical, oncology and other specialty industries.

News for Cardinal Health Stock (CAH)